Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
CircRNA is still in very early days of development, but it is expected to trialled in vaccines, therapeutics and biomarkers trials in the next few years.
CircRNA is still in very early days of development, but it is expected to trialled in vaccines, therapeutics and biomarkers trials in the next few years.
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study